<DOC>
	<DOCNO>NCT02897557</DOCNO>
	<brief_summary>The purpose perform early investigation safety performance Automated Glucose Control ( AGC ) algorithm use OmniPod® Insulin Management System gather clinical data use make improvement modification algorithm subsequent study adult , adolescent child type 1 diabetes .</brief_summary>
	<brief_title>Insulet Artificial Pancreas Early Feasibility Study</brief_title>
	<detailed_description />
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Subjects must meet follow criterion include study : 1 . Age For adult cohort : age 18 65 year ; adolescent cohort : age 12.0 17.9 year ; pediatric cohort : age 6.0 11.9 year 2 . Diagnosed type 1 diabetes least 1 year . Diagnosis base investigator 's clinical judgment . 3 . Total daily dose ( TDD ) insulin ≥ 0.3 units/kg/day A1C &gt; 6 % screen 4 . Currently use insulin pump U100 rapidacting insulin analog pump least 6 month prior start study 5 . Willing use study CGM device one week prior study start duration study 6 . Willing use OmniPod® Insulin Management System study 7 . Willing perform SMBG test studyapproved glucose meter frequency specify study protocol 8 . Willing abide meal recommendation breakfast , lunch dinner study 9 . Willing refrain use acetaminophen , pseudoephedrine , supplemental vitamin C ( &gt; 2000 mg/daily ) entire duration participation study 10 . Willing able sign Informed Consent Form ( ICF ) and/or parent guardian willing able sign ICF . Subjects age ≥ 8 year ask sign assent form . Subjects meet follow criterion exclude study : 1 . A1c &gt; 10 % Screening visit 2 . One episodes severe hypoglycemia require emergency room ( ER ) visit hospitalization within past 6 month 3 . Hypoglycemic unawareness determine score 4 `` R '' responses Clarke Questionnaire 4 . One episodes diabetic ketoacidosis require ER visit hospitalization within past 6 month 5 . Used noninsulin antidiabetic medication within last 30 day 6 . Pregnant lactating , woman childbearing potential acceptable form birth control ( acceptable include abstinence , condom , oral/injectable contraceptive , IUD implant ) 7 . Dermatological condition propose sensor wear sit investigator 's opinion could preclude ability wear Pod and/or Dexcom sensor abdomen 8 . Known history myocardial infarction ( MI ) stroke within past 6 month 9 . Known history seizure disorder 10 . Known history adrenal insufficiency 11 . Current renal hepatic disease 12 . Untreated unstable hypothyroidism celiac disease ( per investigator 's judgment ) 13 . Currently undergo cancer treatment 14 . Currently undergo systemic treatment steroid immunosuppressive medication 15 . History chronic infection would interfere participation study place study personnel undue risk due bloodborne contaminant 16 . Current illness would interfere participation study 17 . Untreated inadequately treated mental illness 18 . Current alcohol abuse per investigator 's judgment 19 . Electricallypowered implant may susceptible RF interference 20 . Currently participate another clinical study test investigational drug device participation clinical study investigational drug use within precede 30 day 21 . Unable follow clinical protocol duration study otherwise deem unacceptable participate study per investigator 's clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>